Biolegend, 361702, Purified anti-human HLA-DR, DP, DQ Antibody, 100μg

HLA-DR, HLA-DP, and HLA-DQ are heterodimeric cell surface glycoproteins comprised of an α (heavy) chain and a β (light) chain. They are expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. Variations in the HLA gene expression are crucial to graft survival.
100μg
Verified Reactivity: Human
Reported Reactivity: Baboon, Cynomolgus, Cat, Dog, Cow
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human PBL
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/mL
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested IHC-P - Verified IP- Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µL volume. For immunohistochemistry on formalin-fixed paraffin-embedded tissue sections, a concentration range of 1 - 10 µg/mL is suggested. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Tü39 has been reported to react with a shared epitope of HLA-DR, HLA-DP, and HLA-DQ. Additional reported applications (of relevant formats) include immunoprecipitation6, in vitro blocking of MLR5, and suppressor cell generation4. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (contact our custom solutions team).
Application References(PubMed link indicates BioLegend citation): Pawelec G, et al. 1985. Hum. Immunol. 12:165. Shaw S, et al. 1985. Hum. Immunol. 12:191. Ziegler A, et al. 1986. Immunobiology 171:77. Pawelec G, et al. 1986. Hum. Immunol. 17:343. (Block) Dai Z, et al. 2009. J. Exp. Med. 206:793. (Block) Pawelec G, et al. 1988. J. Exp. Med. 167:243. (IP)
Product Citations: Lin W, et al. 2023. Commun Biol. 6:447. PubMed Eiva MA, et al. 2022. Eur J Immunol. 52:96. PubMed Gallen C, et al. 2022. Vaccines (Basel). 10:. PubMed Eccles JD, et al. 2020. Cell Rep. 30:351. PubMed Dangaj D, et al. 2019. Cancer Cell. 35:885. PubMed Song S, et al. 2021. Front Immunol. 12:705140. PubMed Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed Donia M, et al. 2015. Cancer Res . 75: 3747-3759. PubMed
RRID: AB_2563139 (BioLegend Cat. No. 361702)
Structure: Ig superfamily, MHC class II, heterodimeric transmembrane protein
Distribution: B cells, activated T cells, monocytes/macrophages, dendritic cells, other APCs
Function: Antigen presentation
Ligand/Receptor: CD3/TCR, CD4
Cell Type: Antigen-presenting cells, B cells, Dendritic cells, Macrophages, Monocytes, T cells
Biology Area: Immunology, Innate Immunity
Molecular Family: MHC Antigens
Antigen References: 1. Thorsby E. 1974. Transplant. Rev. 18:51. 2. Qvigstad E, et al. 1984. Hum. Immunol. 11:207. 3. Servenius B, et al. 1984. EMBO J. 3:3209. 4. Ottenhoff TH, et al. 1985. Hum. Immunol. 13:105. 5. Strassmann G, et al. 1985. Hum. Immunol. 13:125. 6. Trowsdale J, et al. 1985. Immunol Rev. 85:5.
Gene ID: 312231233113311531173119
UniProt: View information about HLA-DR DP DQ on UniProt.org
Clone: Tü39
Regulatory Status: RUO
Other Names: MHC class II, Major Histocompatibility complex II, human leukocyte antigen, HLA
Isotype: Mouse IgG2a, κ